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ABSTRACT
Introduction: Authors have reported increased incidence of multiresistant Pseudomonas 
aeruginosa (MR-PA) infections worldwide over the last decade. Researchers have proposed mul-
tifaceted approaches to control MR-PA infections, but none have been reported in the acquired 
immunodeficiency syndrome (AIDS) setting. Objective and Methods: Herein we report the 
impact of a multifaceted intervention for controlling MR-PA over five years in a hospital with 
AIDS-predominant admissions and describe the clinical characteristics of MR-PA infection in 
our patient population. The clinical outcomes of infected patients and molecular characteristics 
of the isolated strains were used as tools for controlling MR-PA infection rates. Results: Signifi-
cant temporary decrease of new infections was achieved after intervention, although a high level 
of diagnostic suspicion of nosocomial infection was maintained. We obtained 35 P. aeruginosa 
isolates with multiresistant profiles from 13 infected and 3 colonized patients and 2 environmental 
samples. Most of the patients (94%) were immunocompromised with AIDS (n = 10) or HTLV-1 
infections (n = 5). Of the followed patients, 67% had persistent and/or recurrent infections, and 
92% died. We observed differences in the antibiotic-resistance pattern of MR-PA infection/colo-
nization during two outbreaks, although the genetic profiles of the tested strains were identical. 
Conclusions: Therefore, we concluded that early multidisciplinary interventions are essential for 
reducing the burden caused by this microorganism in patients with AIDS. Prolonged or suppres-
sive antibiotic-based therapy should be considered for MR-PA infections in patients with AIDS 
because of the persistence characteristic of MR-PA in these patients.
Keywords: Pseudomonas aeruginosa; disease outbreaks; infection control; molecular epidemiology; 
acquired immunodeficiency syndrome.
INTRODUCTION
Multiresistant Pseudomonas aeruginosa (MR-PA) 
is one of the leading pathogens that cause noso-
comial infections and outbreaks worldwide.1-8 
These infections are usually associated with high 
mortality rates.1-6 Also, in patients with human 
immunodeficiency virus (HIV) or acquired im-
munodeficiency syndrome (AIDS), authors have 
described persistent and recurrent infections 
caused by non-MR-PA strains.9,10 Pulsed-field 
gel electrophoresis (PFGE) is the recommended 
technique for determining the genotypes of no-
socomial pathogens.11 Researchers have used 
it in several studies to confirm the similarity of 
P. aeruginosa strains, suggesting the importance 
of cross-colonization,11,12 and as a tool to control 
nosocomial infections.3,12 Multifaceted strate-
gies using molecular epidemiology approach for 
controlling MR-PA infection outbreaks in im-
munocompromised patients, especially those 
with cancer or admitted to intensive care units 
(ICUs),3,5 have been adopted but none were de-
scribed in patients with AIDS. In this report, we 
describe the surveillance and intervention meas-
ures used for controlling MR-PA infections over 
five years in an infectious disease hospital in Rio 
de Janeiro, Brazil, in which the majority of ad-
mitted patients have AIDS. We also describe the 
clinical evolution of patients with MR-PA infec-
tions or colonization and the antimicrobial sus-
ceptibility profiles and molecular characteristics 
of MR-PA strains recovered from the patients 
and their environments. Increased knowledge 
of the epidemiology and clinical presentations 
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of MR-PA infection in this patient population may improve 
early interventions.
MATERIAL AND METHODS 
Institution and surveillance program 
A prospective program for controlling nosocomial infec-
tions, which used an adaptation of methodologies de-
veloped by the Centers for Disease Control and Preven-
tion, was initiated in April 2002 in a 26-bed (including 
2-4 ICU beds) hospital from Fundação Oswaldo Cruz 
(FIOCRUZ).13-15 The adaptation concerned the applica-
tion of surveillance in the entire hospital and used to 
identify nosocomial infections in patients with AIDS 
considered to be acquired at the hospital.16 Infections 
were considered nosocomial if they first appeared 48h 
after admission. Infections that were likely incubating 
before hospital admission were not considered noso-
comial. All clinical and surveillance cultures obtained 
from every admitted patient were observed daily for 
early identification and control of multiresistant patho-
gens from April 2002 to February 2007. Three antibi-
otic susceptibility patterns of MR-PA were considered: 
I) multidrug-resistant P. aeruginosa (MDR-PA) was 
indicated by strains resistant to carbapenems and, con-
comitantly, at least two other classes of antipseudomonal 
antibiotics: penicillins, cephalosporins, monobactams, 
aminoglycosides, and fluoroquinolones; II) extensive 
drug-resistant P. aeruginosa (XDR-PA) was indicated by 
strains resistant to all classes of antipseudomonas anti-
biotics with the exception of polymyxin B; III) carbap-
enem-resistant P. aeruginosa (CR-PA) was indicated by 
strains resistant only to carbapenems. All the patients’ 
medical records were reviewed to confirm the prospec-
tively collected data.
During MR-PA outbreaks, in addition to clinical cul-
tures a differential surveillance was performed, which 
included rectal swab samples for MR-PA detection ob-
tained from patients hospitalized in the same room or 
unit whenever an MR-PA isolate was identified. Cultures 
of clinical surface samples were obtained during the first 
outbreak in the ICU where the majority of the patients 
with acquired MR-PA were hospitalized. These samples 
were collected before cleaning from furniture, equipment, 
sinks, ventilation ducts, air conditioning intake grills, air 
conditioning filters, compressed air tubes, patients’ nebu-
lizers and respiratory circuits with sterile cotton-tipped 
swabs moistened with transport media. Water from air 
conditioner compressors and humidifiers was also sam-
pled. During the second outbreak, in November 2006, the 
following samples were collected from three areas of 
the ICU and from two wards as part of another research 
protocol also approved by the institutional ethics com-
mittee: 250 L of air samples taken using an MAS-100 
air sampler (Merck & Co., Inc., Whitehouse Station, NJ, 
USA) at a distance of 1.5-2.0 m from the patients beds 
and 1.5 m from the floor, two surface samples taken in 
each ICU and ward area using the in print technique with 
RODAC plates, and samples taken from the hands 
(washed in a 100 mL 0.1% peptone solution in sterile 
bags) of personnel who dealt with MR-PA-positive pa-
tients during environmental sampling.
Laboratory procedures 
Clinical samples and rectal swabs were inoculated onto 
MacConkey agar (Merck & Co., Inc.) and cetrimide 
agar (Merck & Co., Inc.) plates. Environmental surface 
swabs were plated on sheep blood agar. Cetrimide agar, 
MacConkey agar, and salt mannitol agar (Merck & Co., 
Inc.) were used for air sampling. The plates were incubated 
at 37ºC for 48h. Colonies that contained Gram-negative 
rods were subcultured onto blood and MacConkey agar 
plates and incubated for 24h. All oxidase-positive bacilli 
and non-lactose fermenting growths were identified as 
P. aeruginosa using conventional biochemical tests.
The antibiotic susceptibility of the isolates was tested 
using the disk-diffusion method according to Clinical and 
Laboratory Standards Institute recommendations.17 Sus-
ceptibility to polymyxin B was verified using the E-test. 
Resistant strains included those with intermediate suscep-
tibility. Screening of the strains for metallo-β-lactamase 
(MBL) production using a ceftazidime disk in the presence 
of 2-mercaptopropionic acid and polymerase chain reac-
tion for detection of the blaSPM-1, blaIMP, and blaVIM 
genes were performed.18 DNA macrorestriction using 
Spel followed by PFGE for molecular typing of isolates 
was carried out as well.19 Restriction fragment profiles of 
the genomic DNA of MR-PA strains were compared us-
ing visual inspection and the GelCompar II software pro-
gram (version 3.5; Applied Maths, Sint-Martens-Latem, 
Belgium) and analyzed using the Tenover criteria (1995).20
Clinical characteristics of MR-PA infections
The clinical characteristics of MR-PA infections were clas-
sified according to three categories: I) persistent infec-
tion, in which the microorganism was maintained in the 
same or another clinical material for at least 21 days re-
gardless of symptoms or treatment; II) recurrent infection, 
in which clinical symptoms of infection reinitiated and the 
MR-PA was isolated in the same or another biological mate-
rial after completion of treatment; and III) single infection, 
which was an unique infectious episode without persistence 
or recurrence. Treatment failure was considered in cases 
with any clinical deterioration or persistence of the micro-
organism in clinical materials resulting in a change in the 
antibiotic-based therapy or death.
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RESULTS 
Admitted patients
HIV (850 patients) and HTLV-1 (130 patients) infections 
were the main clinical conditions of the admitted patients 
(54% of admissions). Also, readmissions occurred in a high 
proportion of the patients (654 readmissions among 1,814 
admissions) during the 5-year study period. An average of 
35 clinical bacteriological cultures per 100 patient-days was 
performed in the hospital over this period.
Description of outbreaks
Figure 1 shows the monthly distribution and resistance pat-
terns of P. aeruginosa isolates during the study period. The 
mean incidence density of MR-PA infection (using for calcula-
tion only the first MR-PA isolate obtained from each patient) 
was 0.53/1,000 patient-days from April 2002 to February 2007. 
However, it was 2.8/1,000 patient-days from November 2004 
to March 2005 (first outbreak) and 2.1/1,000 patient-days from 
November 2006 to February 2007 (second outbreak).
The onset of the first MR-PA outbreak coincided with iden-
tification of the XDR-PA-infected index patient in the ICU in 
September 2004 (Figure 1). This patient came from another 
nearby hospital; two months before detection of the first out-
break with recovery of 15 MDR-PA and 2 XDR-PA strains from 
six patients. After an intervention program for controlling the 
MR-PA outbreak initiated in November 2004, the occurrence 
of MR-PA decreased significantly, with only one new CR-PA 
infection detected over a 1-year period (September 2005 to 
October 2006). During the second outbreak, which began in 
November 2006, we had seven XDR-PA isolates from five pa-
tients but detected no MDR-PA or CR-PA strains.
Culture results, clinical presentations and outcomes
Forty-four patients had P. aeruginosa infections or coloni-
zation during the study. Twenty-six patients had isolates 
with non-CR-PA/MDR-PA/XDR-PA susceptibility patterns. 
Two patients had isolates with these resistance patterns 
detected before 24 h of hospital admission. One of these 
patients had been admitted previously during the first out-
break, but a rectal swab obtained from her was negative for 
MR-PA at that time. Of 16 patients in whom MR-PA devel-
oped during hospitalization in the study period, 15 were im-
munocompromised (94%) with AIDS (n = 10) or HTLV-1 
(n = 5) with urinary tract infections (UTIs) (Table 1). Thir-
teen patients had MR-PA infections, whereas three had MR-
PA colonization. Rectal swabs were positive for MR-PA in 
only one patient, who had MDR-PA isolates recovered from 
other clinical samples. Table 1 shows the age, sex, underlying 
and comorbid condition, length of hospital stay and admis-
sion to the ICU prior to MR-PA infection, and laboratory 
data for the MR-PA isolates obtained from these 16 patients.
Among six patients in whom MR-PA infection/coloni-
zation developed during the first outbreak, four were un-
dergoing hemodialysis (patients #5 to #8 in Tables 1 and 2) 
and four (patients #3 to #5 and #7) were in the ICU when 
they acquired it. In comparison, among the five patients in 
whom these infections/colonizations developed during the 
second outbreak, none were undergoing hemodialysis and 
three were in the ICU when they acquired it (Table 1). Each 
new MR-PA-positive patient had been hospitalized in close 
proximity to another previously MR-PA-positive patient 
in the ICU or other hospital ward. Table 2 lists the types of 
infections, therapies for Gram-negative bacterial infections 
after MR-PA isolation, MR-PA infection treatment failures, 
infection classifications, and deaths associated with MR-PA 
infection and/or colonization during the study period. 
Septicemia or infections related to the use of invasive de-
vices predominated among patients (13/19, 68%). Excluding 
one patient who was lost to follow-up (transferred to another 
hospital), 58% (n = 7) of the remaining 12 infected patients 
had one MR-PA infection treatment failure. Also, eight 
patients (67%) had persistent and/or recurrent MR-PA infec-
tions, and 11 (92%) died despite receiving therapy and medi-
cal support (Table 2). The overall mortality rate associated with 
MR-PA infection during the study period was 80% (12/15). The 
average time span between obtaining the first and last clinical 
MR-PA-positive samples in eight patients who had persistent 
and/or MR-PA recurrent infections was 55.3 days (median, 29 
days; range, 21-195 days). Five patients in the first outbreak 
(83%) and one in the second outbreak (20%) died. The patient 
who survived in the first outbreak died of recurrent MDR-PA 
septicemia six months after his first MR-PA infection (patient 
#8). The patient who died during the second outbreak (patient 
#14) had untreated XDR-PA bacteremia one month before de-
velopment of XDR-PA ventilator-associated pneumonia (VAP).
Figure 1: Epidemiologic curve showing the P. aeruginosa 
isolates obtained monthly from patients. Total 
P. aeruginosa isolates (PA, black bar) and MDR-PA (red 
bar), XDR-PA (blue bar), and CR-PA (green bar) isolates 
are shown. The arrows indicate when the infection control 
interventions were initiated. 
Persistent multiresistant Pseudomonas aeruginosa infection
N
u
m
b
er
 o
f 
is
o
la
te
s
A
pr
-0
2
Ju
l-0
2
O
ct
-0
2
Ja
n-
03
A
pr
-0
3
Ja
n-
04
Ju
l-0
3
A
pr
-0
4
O
ct
-0
3
Ju
l-0
4
O
ct
-0
4
Ja
n-
05
A
pr
-0
5
Ju
l-0
5
O
ct
-0
5
Ja
n-
06
A
pr
-0
6
Ju
l-0
6
O
ct
-0
6
Ja
n-
07
Total of MDR-PA XDR-PA CR-PA 
PA isolates strains strains strains
12
10
8
6
4
2
0
BJID-4-JUN ARTE FINAL.indd   314 28/07/11   13:30
315
Gomes, Machado, Conceição et al.
Table 1. Epidemiological data and laboratory results of patients with MR-PA infection and/or colonization*
Patient Sex/ Clinical  Other Length of Sample - Time span
 age  condition diagnoses  hospital  susceptibility between first 
 (years)   stay†/  pattern, date and last MR-PA  
    ICU of sample positive 
     admission†  cultures (days)
1 M/43 HAM/TSP MRSA sepsis,  4/No Urine: MDR-PA,  21  
  with  renal failure,   05/21/02; 
  recurrent respiratory failure  CVC tip: XDR-PA,   
  UTI   06/10/02 
2 M/33 AIDS Cryptococcal meningitis, 36/Yes Blood: XDR-PA,  2 
   infected dermatitis,  (PFGE tested) 
   Pneumocystis carinii  09/08/04; 
   pneumonia, Respiratory  BAL: XDR-PA,  
   failure; last CD4:406 cells/μL‡  09/09/04 
3 M/45 AIDS Neurologic disease,  5/Yes Tracheal aspirate: 27 
   DM type 2, COPD,   MDR-PA, 11/12/04; 
   HCV-positive,   BAL: MDR-PA (PFGE 
   Enterococcus faecalis UTI,   tested), 11/29/04; 
   respiratory failure; last   tracheal aspirate: 
   CD4: 98 cells/μL;   XDR-PA, 12/08/04; 
   viral load: 19,000   vascular catheter tip:  
   copies/mL‡  XDR-PA, 12/08/04
4 M/25 AIDS CMV esophagitis,  9/Yes Tracheal secretion: - 
   pneumothorax, respiratory   MDR-PA (PFGE tested), 
   failure, MRSA colonization;   11/30/04 
   last CD4: 324 cells/μL;    
   viral load: 710,000 copies/mL‡    
5§ M/50 AIDS Febrile neutropenia,  20/Yes Tracheal secretion: - 
   disseminated Mycobacterium   MDR-PA, 20,000 
   tuberculosis, renal failure,   CFU, 12/19/04 
   hepatic failure, pancreatitis   
6§ F/43 AIDS Neurologic disease,  8/No Vascular catheter tip: 28 
   Salmonella and Enterococcus   MDR-PA, 03/03/05; 
   species sepsis, MRSA CVC  urine MDR-PA, 
   sepsis, bronchoaspiration,   03/30/05 
   renal failure   
7§ M/59 Leptospirosis Renal failure, 33/Yes Two vascular  29 
   atrial fibrillation,   catheter tips: MDR-PA, 
   MRSA CVC sepsis  03/21/05; urine: 
     MDR-PA, 03/28/05 
     and 03/31/05; 
     rectal swab: MDR-PA,  
     04/06/05; 
     vascular catheter tip:  
     MDR-PA, 04/18/05; 
     tracheal secretion:  
     MDR-PA, 04/18/05 
8§ M/54 AIDS Febrile neutropenia,  8/No Blood: MDR-PA, 195 
   cryptococcosis,    03/10/05; 
   high blood pressure,   urine: MDR-PA, 
   chronic renal failure,   03/22/05; 
   MRSA colonization  blood: MDR-PA, 
     9/21/05 
(Cont.)
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Table 1. Epidemiological data and laboratory results of patients with MR-PA infection and/or colonization* 
Patient Sex/ Clinical  Other Length of Sample - Time span
 age  condition diagnoses  hospital  susceptibility between first 
 (years)   stay†/  pattern, date and last MR-PA  
    ICU of sample positive
     admission†  cultures (days)
9 F/60 HAM/TSP  Cutaneous T-cell 53/Yes Urine: MDR-PA,  - 
  with lymphoma, hemorrhagic   07/06/05 
  recurrent stroke, high  
  UTI blood pressure,  
   DM-type II, MDR  
   Escherichia coli UTI,  
   MRSA osteomyelitis  
10 F/64 HAM/TSP E. coli UTI,  9/No Urine: MDR-PA 88 
  with hydronephrosis   (PFGE tested), 
  recurrent with renal calculi,   08/15/05; 
  UTI decubitus ulcers   urine: XDR-PA, 
   and osteomyelitis,   11/10/05 
   MRSA colonization 
11 F/47 AIDS Hepatitis C,  2||/Yes Urine: CR-PA,  - 
   decubitus ulcers,   05/31/06 
   UTI, MRSA colonization  
12 M/56 AIDS Hyperparathyroidism,  85/Yes Blood: XDR-PA,  21 
   HIV dementia,   11/16/06; 
   CDAD; last CD4:   blood: XDR-PA 
   9 cells/μL;   (PFGE tested), 
   viral load: > 100,000   12/06/06 
   copies/mL‡  
13 F/75 HAM/TSP  Streptococcus 28/No Urine: XDR-PA,  - 
  with species sepsis  50,000 CFU/mL  
  urinary   (PFGE tested),  
  sepsis   11/11/06 
14 M/31 AIDS CMV meningitis,  174/Yes Blood: XDR-PA,  33 
   CDAD (pseudomembranous   (PFGE tested),  
   colitis), MDR Klebsiella   11/24/06; 
   pneumoniae CVC sepsis,   BAL: XDR-PA,  
   respiratory failure;   12/26/06   
   last CD4: 6 cells/μL‡  
15 M/26 AIDS Febrile neutropenia,  32/No Urine: XDR-PA, - 
   MRSA sepsis  80,000 CFU/mL,  
     01/25/07
16 M/69 HAM/TSP  Iatrogenic 31/Yes Urine: XDR-PA,  - 
  with urinary  pneumothorax,  02/02/07 
  sepsis decubitus ulcers 
BAL, bronchoalveolar lavage; CDAD, Clostridium difficile-associated diarrhea; CFU, colony-forming unit; CMV, cytomegalovirus; 
COPD, chronic obstructive pulmonary disease; CVC, central vascular catheter; DM, diabetes mellitus; F, female; HAM/TSP,  
HLTV-I associated myelopathy/tropical spastic paraparesis; HCV, hepatitis C virus; M, male; MRSA, methicillin-resistant  
Staphylococcus aureus.
*MR-PA includes all resistance patterns(MDR-PA, XDR-PA, and CR-PA).
†Previous to MR-PA infection or colonization.
‡CD4 and viral load for HIV-positive patients when available and collected less than 6 months before MR-PA infection/ 
colonization.
§Performance of hemodialysis when MR-PA was acquired.
||Discharged from the study hospital 5 days before this admission.
Persistent multiresistant Pseudomonas aeruginosa infection
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Table 2. Clinical presentations, antibiotic regimen, and outcomes in patients with MR-PA infection or colonization*
Patient Type of infection/ Antibiotic Treatment Infection Death during
 colonization regimen† failure‡ classification§ hospitalization
1 UTI Empiric cefepime No Persistent  
  and guided by culture for   infection 
  21 days, associated with    
Yes||
 
  empiric amikacin and    
  guided by culture for 7 days    
 CVC sepsis Not treated N/A -
2 VAP and The patient had received N/A Single episode Yes|| 
 septicemia cefepime and levofloxacin  
  for 14 days and was receiving     
  treatment for Pneumocystis  
  carinii pneumonia 
3 VAP Empiric levofloxacin for 2 days,  Yes Persistent  
  cefepime for 20 days,   infection 
  empiric polymyxin B for    Yes|| 
  2 days, amikacin for 16 days   
 CVC infection Not treated N/A Recurrent infection
4 VAP Empiric cefepime for 3 days,  Yes Single episode Yes|| 
  empiric imipenem for 4 days 
5 Respiratory tract N/A N/A N/A Yes 
 colonization
6 CVC infection Not treated. The patient  N/A Persistent 
  was receiving treatment  infection 
   for Salmonella and Enterococcus  
  species sepsis with ampicillin    Yes|| 
  and gentamicin    
 UTI Empiric imipenem Yes - 
  for 2 days, empiric cefepime  
  for 1 day  
7 CVC sepsis Cefepime for 15 days Yes Persistent infection  
 Septicemia Piperacillin-tazobactam  Yes - Yes 
  for 4 days   
8 CVC sepsis Cefepime for 8 days  No Single episode No 
  for febrile neutropenia,   
  MDR-PA growth in blood,    
  had CVC removed and then   
  received cefepime for 14 days,   
  piperacillin-tazobactam for    
  11 days, and piperacillin-tazobactam  
  and levofloxacin for 14 days 
 Septicemia Empiric cefepime for 1 day N/A Recurrent infection Yes||
9 Urinary sepsis Empiric imipenem for 2 days, Yes Single episode Yes 
  cefepime for 9 days 
10 UTI Cefepime for 22 days,  No Single episode No 
  transferred to another hospital     
  for J ureteral stent insertion   
 
 
 UTI Polymyxin B for 16 days Not Recurrent Yes 
   determined infection 
(Cont.)
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Table 2. Clinical presentations, antibiotic regimen, and outcomes in patients with MR-PA infection or colonization* 
Patient Type of infection/ Antibiotic Treatment Infection Death during
 colonization regimen† failure‡ classification§ hospitalization
11
 
Urinary sepsis Empiric cefepime and  Yes Single episode Yes 
  guided by culture for 14 days 
12  Empiric piperacillin- N/A 
  tazobactam for 7 days,   
  ciprofloxacin for 6 days  
 Septicemia   
Persistent 
No 
  Cefepime and polymyxin B  No 
infection
 
  for 3 days, polymyxin B  
  alone for 6 days     
13 Urinary tract
 
N/A  N/A N/A No 
 colonization
14 Bacteremia Not treated; the patient was N/A Persistent 
   receiving treatment for MDR K.   infection 
  pneumoniae CVC sepsis with    
  piperacillin-tazobactam for 10 days    Yes 
  and meropenem for 7 days    
 VAP Empiric cefepime for 3 days,  Yes - 
  polymyxin B for more than 21 days  
15 Urinary tract N/A N/A N/A No 
 colonization 
16 UTI Empiric cefepime for 2 days;  Lost to Lost to No 
  patient transferred to another  follow-up follow-up  
  hospital  
CVC, central vascular catheter; N/A, not applicable.
*MR-PA includes the entire resistance pattern (MDR-PA, XDR-PA, and CR-PA).
†Described therapy only for Gram-negative bacteria after MR-PA detection.
‡Treatment failure: clinical deterioration or persistence of the microorganism in clinical materials resulting in a request to 
change the antibiotic-based therapy or resulting in death.
§Infection classification: I) recurrent infection: clinical symptoms of infection reinitiated and isolation of the MR-PA in other or 
same biologic materials after completion of treatment; II) persistent infection: maintenance of the microorganism in the same 
or other clinical materials for at least 21 days independent of symptoms or treatment; III) single infection: unique episode of 
infection with no recurrent or persistent infection.
||Death before last microbiological result with recovery of MR-PA.
Six patients (patient #1, #3, #8 to #11) with MR-PA 
infections were treated with cefepime alone or in com-
bination therapy with other antipseudomonal antibiotics 
considered adequate according to laboratory test results 
and time of initiation and duration of therapy. However, 
three of these patients – two with urinary sepsis (patients 
#9 and #11) and one with VAP (patient #3) – had no re-
sponses to 9, 14, and 20 days into antibiotic treatment, 
respectively. In addition, in patient #3, MDR-PA regrew 
in a bronchoalveolar lavage (BAL) sample on the 15th day 
of treatment with cefepime, and XDR-PA grew in a tra-
cheal aspirate and on a catheter tip on the 4th day after 
discontinuation of cefepime-based treatment.
Results of culture of environmental samples
MDR-PA was cultured from 2 of 12 (17%) environmen-
tal samples (water obtained from a humidifier in one pa-
tient and a respiratory circuit condensate from the other) 
collected during the first outbreak in the ICU, which had only 
two beds at that time. None of the cultures of clinical surfaces, 
air, or health care workers’ hands in the ICU and wards obtained 
during the second outbreak were positive for P. aeruginosa.
Antibiotic susceptibility profiles and molecular 
analysis of MR-PA isolates
All P. aeruginosa isolates (n = 94) underwent antibiotic 
susceptibility testing. Thirty-three isolates from patients – 
20 MDR-PA, 12 XDR-PA, and 1 CR-PA – had antibiotic-
Persistent multiresistant Pseudomonas aeruginosa infection
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resistant profiles (Figure 1). The MDR-PA strains were 
universally resistant to gentamicin, amikacin, cefotaxi-
me, ticarcillin-clavulanic acid, imipenem, meropenem 
(tested since January 2005), ciprofloxacin, levofloxacin 
(tested since September 2004), norfloxacin, and trimeth-
oprim-sulfamethoxazole. Fifteen MR-PA strains isolated 
from six patients in the first outbreak were susceptible 
to cefepime, ceftazidime, and polymyxin B; one was sus-
ceptible to aztreonam; and six were susceptible to piper-
acillin-tazobactam.
The index case, five of 11 patients in the outbreaks 
and one patient from the interepidemic period had one 
MDR-PA or XDR-PA isolate each analyzed by PFGE 
(Table 1, Figure 2). The two MR-PA-positive environ-
mental strains also underwent PFGE. Figure 2 shows 
that all of the PFGE-tested strains had identical ge-
netic profiles and belonged to the São Paulo clone 
(the SPM-1 strain was matched with MR-PA isolates). 
However, all of these strains were negative for tested MBL 
production.
Figure 2: PFGE patterns of 10 isolates of MDR-PA and 
XDR-PA. Lanes 1 and 12, PFGE Lambda (molecular markers). 
Lanes 2-11, PFGE-detected patterns in 10 strains of MDR-
PA or XDR-PA: 2, XDR-PA, patient 1 (index case), blood; 3, 
XDR-PA, patient 2 (1º outbreak), BAL; 4, MDR-PA, patient 
3, tracheal aspirate (1º outbreak); 5 and 6, MDR-PA, swab 
from condensate of the ventilator circuit of patient 2 (1º 
outbreak); 7, MDR-PA, water sample from a humidifier 
(1º outbreak); 8, XDR-PA, patient 6, urine (non-outbreak 
case); 9, XDR-PA, patient 7, urine (2º outbreak); 10, XDR-
PA, patient 8, blood (2º outbreak); 11, XDR-PA, patient 9, 
blood (2º outbreak). Lane 13, São Paulo MLB strain. 
Infection control intervention and education  
program 
Infection-control measures involved outbreak notification, 
cohort of patients and professionals, temporary closing of 
the ICU to new admissions during the first outbreak, con-
tact precautions for all colonized and/or infected patients, 
environmental disinfection, and a review of all disinfection 
and sterilization processes. During the first outbreak, the 
infection control team reviewed the health care providers’ 
work process to minimize cross-transmission of MR-PA, 
including technicians involved in performing hemodialysis 
from a contracted service. Hospital personnel repaired a wa-
ter leak in the compressed air system and changed the air 
conditioning filters in the ICU. Furthermore, the hospitals 
newly constructed ICU opened in June 2006. Members of 
the infection control committee systematically presented the 
surveillance results, including results of molecular analysis 
of the P. aeruginosa strains and the patients’ outcomes, to 
the hospital staff in educational activities carried out 
over the entire study period to ensure their commitment to 
infection control measures. However, the hospitals’ nursing 
staff underwent a great turnover in March 2005, whereas 
the physician and nursing staff did so in November 2006. 
DISCUSSION
Researchers have demonstrated the difficulty of controlling 
MR-PA infections in hospitals where the agent is already en-
demic.21 However, a multifaceted infection control program 
can temporarily control the transmission of this infection.3,5 
To the best of our knowledge, this is the first report to de-
scribe the epidemiological characteristics of MDR-PA/XDR-
PA infection outbreaks that were temporarily controlled but 
not eradicated in patients with AIDS, in whom persistent 
MR-PA infections likely increase the risk of transmission.
The reported overall incidence of P. aeruginosa carriage 
in ICUs and oncological/hematological or medical wards 
has varied from 11.7% to 37.0%.22,23 Many authors have ad-
vocated the use of surveillance cultures to improve the con-
trol of infections with multiresistant pathogens in high-risk 
settings, but the benefit of this strategy remains to be evalu-
ated.24 We agree with previous observation that surveillance 
of patients with MR-PA infections must be accompanied by 
an early implementation of an intervention program when-
ever required.3 In the present study, we based the surveil-
lance program on clinical microbiological examinations of 
patients’ samples requested by infectious disease specialists, 
who usually have high diagnostic suspicion of nosocomial 
infections. In addition, we systematically used surveillance 
cultures with rectal swabs during the two outbreaks; how-
ever, we used them in a non-systematic manner between 
outbreaks. We performed rectal swabs only, as respiratory 
and urinary samples were normally used for diagnosis of 
infections. In addition, gastrointestinal carriage appears to 
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be a prerequisite for P. aeruginosa colonization and/or infec-
tion at other sites, and the intestinal tract is considered the 
most important reservoir of P. aeruginosa.22,25 However, 
the sensitivity of rectal swabs in detecting small inocula is 
suboptimal,22 and patients with colonization at sites other 
than the intestinal tract may have been missed.25,26 Our in-
tention was to perform surveillance of patients with MR-PA 
infections in a real-life hospital setting with limited resourc-
es so that the surveillance program would be easy to accom-
plish. This may have been a limitation of our study, though, 
as well as our lack of use of selective antimicrobial media 
for rectal swabs to detect antibiotic-resistant P. aeruginosa.23
Patients with MR-PA colonization and/or infections 
frequently have contamination of their hands, clothes, and/
or immediate surroundings, which raises the possibility of 
transmission to other patients either directly or via con-
tact with hospital staff or contaminated equipment.1,2,6,27 
During the first outbreak, four patients were undergoing 
hemodialysis performed by the same technician. We con-
trolled this epidemic after we reviewed this technician’s 
work and assigned different technicians for each patient. 
Nevertheless, we did not obtain cultures from the hands 
of the original technician. This horizontal transmission of 
MR-PA infections was supported by the findings of geno-
typing analysis of MR-PA isolates obtained from patients 
and environmental and of the temporal and spatial associa-
tion among MR-PA cases.
As previously described, we obtained samples of water 
and wet surfaces contaminated with P. aeruginosa in our sur-
veillance report only in close proximity to infected/colonized 
patients.3,27 Studies showed that airborne dissemination can 
have a role in the transmission of P. aeruginosa.27,28 Howev-
er, we did not detect any P. aeruginosa isolates using an air 
sampler that has equivalent results of the sixth stage of an 
Andersen air sampler.29 The small number of air samples ob-
tained in our study may have influenced this result. The newly 
renovated ICU in our hospital (with isolation rooms and a 
modern ventilation system) may have contributed to tem-
porary control of the infection, as suboptimal ICU designs 
layouts such as our previous one have been associated with 
MR-PA infection outbreaks.4 The organism’s panantibiotic-
resistance pattern and biofilm formation most likely played 
important roles in extending the outbreaks.2 Also, hospital 
personnel shortage30 or, as in our case, high hospital staff 
turnover may be related to MR-PA infection outbreaks or 
initial difficulty in controlling them. In addition, the second 
outbreak may have been related to readmission of an MR-PA 
colonized patient which was likely colonized during hospi-
talization at the time of the first outbreak; however, we cannot 
rule out other explanations not fully explored in this study.
The continuous training program on prevention and 
control of nosocomial infections given to all health care 
professional categories was an essential tool for controlling 
MR-PA infections in our hospital, as well.5,12 We used several 
educational activities and resources such as posters, folders, 
and signs during the study period. Continuous education is 
important even in hospitals specialized in treating infectious 
diseases, where all health care workers have some knowl-
edge about the risk of nosocomial infections. Keeping the 
clinical staff informed about the surveillance results, clinical 
outcomes of infected patients, and, when feasible, molecu-
lar characteristics of isolated strains is essential to increase 
and maintain their commitment to controlling nosocomial 
infection. This is especially important for high-risk popula-
tions while new preventive and treatment strategies for MR-
PA infections are being developed.
We observed some differences in the antibiotic suscep-
tibility patterns between the two outbreaks, although the 
genetic profiles of the tested strains were identical. The anti-
biotic-resistance patterns of MR-PA isolates changed during 
the five-year study period, with MR-PA strains becoming 
resistant to almost all of the antibiotics tested except poly-
myxin B. Six patients had P. aeruginosa isolates susceptible 
or less resistant to the antibiotics tested prior to detection of 
more antibiotic-resistant strains. All of these patients had 
received cefepime alone or in combination therapy before 
isolation of P. aeruginosa strains with the patterns of greater 
antibiotic resistance. Therefore, although cross-colonization 
was an important feature of these outbreaks, antimicrobial 
pressure was also likely responsible for these differences in 
antibiotic resistance. However, in settings of infrequent an-
timicrobial use, frequent cross-transmission events can con-
tribute to high antibiotic resistance rates.31 We did not com-
pletely assess the resistance mechanism in our tested strains, 
but all of the isolates were negative for MBL production. 
Unfortunately, we did not have the necessary resources to 
study other antibiotic-resistance mechanisms previously de-
scribed in MR-PA.8,32 MDR-PA infections probably acquired 
new or derepressed resistance mechanisms during the study 
period. Sequential emergence of resistance is likely due to 
the administration of different antibiotics at different time 
periods following the development of resistance.33
The high mortality rates in this study demonstrated 
the burden of MR-PA infections in immunocompro-
mised patients. This may have reflected the immuno- 
compromised states of the patients as well as the multi-
drug resistance and possible enhanced virulence of the 
outbreak strain.2 All patients who died had severe co-
morbidities or opportunistic diseases that likely contrib-
uted to the high mortality rates. Inappropriate empirical 
antimicrobial-based therapy and delays to initiate appro-
priate antimicrobial-based therapy are both detrimental 
to patient outcome.34 Authors have described failure of 
cefepime-susceptibility breakpoints to predict clinical out-
comes35 as well as the requirement of achieving adequate 
drug exposure to be successful in treating patients with 
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P. aeruginosa infections.36 Additionally, a multivariate 
logistic regression analysis demonstrated P. aeruginosa 
infection to be independently associated with treatment 
failure in cefepime-patients.37 We did not evaluate any of 
these features in the present study; therefore, we cannot 
attribute the high mortality rates to the antibiotics used. 
Investigators have observed relapsed or recurrent infec-
tions caused by non-multiresistant P. aeruginosa in patients 
with AIDS but without any impact on mortality.9 In addition, 
authors have described persistent respiratory infections with 
sequentially obtained non-multiresistant P. aeruginosa strains 
in AIDS patients.10 The incidence of treatment failure and per-
sistent or recurrent infections was markedly elevated in the 
present study. Also, persistent and recurrent infections were 
observed in patients with and without AIDS. The criteria used 
for identification of persistent and recurrent infections were 
based on clinical and antibiotic susceptibility data but not 
the genetic profiles of the isolated strains, as we did 
not perform molecular typing of all of the MR-PA iso-
lates (only of randomly preserved strains). In addition, 
we obtained rectal swabs only from patients who were 
negative for MR-PA in close contact with a MR-PA posi-
tive patient. Consequently, we did not investigate coloni-
zation of P. aeruginosa in the gastrointestinal tract of pa-
tients with MR-PA infections or colonization at other sites. 
The investigation of MR-PA colonization in the gastroin-
testinal tract may contribute to understanding the charac-
teristics of persistent and/or recurrent infections caused by 
MR-PA in these patients. Therefore, more investigations of 
persistent infections caused by P. aeruginosa are necessary 
in this era of antimicrobial resistance in patients other than 
those with cystic fibrosis in whom this feature is well recog-
nized.38,39
Regarding patients with symptomatic HTLV-1 infec-
tions, studies have suggested that they are at increased risk 
for UTIs.40 Physicians have used prolonged urinary cath-
eterization in these patients because of their myelopathy 
and/or tropical spastic paraparesis. Urinary catheterization 
and UTIs are both recognized risk factors for MR-PA in-
fection.41,42
CONCLUSIONS
A multifaceted infection control program can control and 
prevent temporarily the transmission of MR-PA infection 
in the AIDS setting. Broader investigation of patient envi-
ronments as well as risk factors for MR-PA infection and/or 
colonization may help increase understanding of the mul-
tifactor origin of MR-PA infection and develop local rec-
ommendations for prevention and control of the infection. 
Infection control programs and diagnosis and treatment 
approaches of MR-PA infections in AIDS patients must con-
sider the persistent characteristic of MR-PA infections in 
this population.
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